Guardant Health (GH) EBIT Margin (2017 - 2026)

Guardant Health has disclosed EBIT Margin across 10 years of filings, most recently posting 40.23% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 40.23%, up 1435.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 41.43% (up 1735.0% YoY), and the FY2025 annual result was 44.53%, up 1550.0% from the prior year.
• EBIT Margin came in at 40.23% for Q1 2026 at Guardant Health, up from 42.95% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 37.33% in Q3 2025 to a low of 128.34% in Q1 2022.
• The 5-year median for EBIT Margin is 62.42% (2024), against an average of 79.1%.
• Across the five-year window, EBIT Margin slumped 2431 bps in 2022 and soared 6497 bps in 2024, its largest moves.
• Guardant Health's EBIT Margin stood at 115.15% in 2022, then retreated by 11 bps to 127.38% in 2023, then surged by 51 bps to 62.42% in 2024, then jumped by 31 bps to 42.95% in 2025, then gained by 6 bps to 40.23% in 2026.
• The last three EBIT Margin figures came in at 40.23% (Q1 2026), 42.95% (Q4 2025), and 37.33% (Q3 2025), per Business Quant data.